DEBx Medical, an Amsterdam-based leader in advanced wound care, has announced the successful completion of its second investment round, spearheaded by TVM Capital Healthcare. This new funding will accelerate DEBx Medical’s global market expansion, aiming to bring innovative solutions to chronic wound management worldwide.

Investment Supports Global Expansion and Product Commercialization

The latest round of funding builds on a successful initial investment and underscores growing confidence in DEBx Medical’s breakthrough approach to chronic wound treatment. The company’s flagship product, DEBRICHEM®, is a topical desiccating agent specifically designed to eradicate biofilm and infection from chronic wounds, enhancing healing outcomes for patients.

“This additional funding from TVM Capital Healthcare will expedite the commercialization of DEBRICHEM® across key global markets, allowing us to reach more patients suffering from non-healing wounds,” stated Tristan de Boysson, Managing Partner of TVM Capital Healthcare. “Our continued commitment through the TVM Healthcare Afiyah Fund aims to bring innovative wound care solutions to regions like the MENA, especially the Kingdom of Saudi Arabia.”

Addressing a Critical Healthcare Challenge

Chronic wounds present a substantial burden on healthcare systems globally, often leading to increased costs, complications, and a decline in patient quality of life. DEBRICHEM® offers a unique, CE and ISO-certified solution, demonstrating remarkable effectiveness in completely eradicating biofilm and infection, with thousands of patients successfully treated since its market launch.

“We are thrilled to secure this new round of funding, marking a pivotal step in DEBx Medical’s journey toward global expansion,” said Bert Quint, CEO of DEBx Medical. “This investment will enable us to enter strategic markets, where the need for innovative chronic wound solutions is critical. The strong support from our investors validates our vision and the transformative potential of DEBRICHEM® in the wound care sector.”

Strengthening Innovation and Market Reach

DEBRICHEM® has already seen significant adoption in Europe and parts of the MENA region, including Saudi Arabia. The product’s ability to disrupt biofilm and eliminate infection has proven essential in initiating the healing process for chronic wounds that were previously resistant to treatment.

Driving Future Growth

Beyond geographic expansion, DEBx Medical plans to intensify its research and development efforts, focusing on creating additional solutions for chronic wound care. The company’s commitment to clinical data and evidence-based medicine will guide its strategy as it broadens its product portfolio and addresses unmet needs in the treatment of non-healing wounds.